Microscope

Advancing medicines

Light bulb shining

Solving therapeutic problems

Group of 3 people

Improving lives

Aquestive is a specialty pharmaceutical company that advances and commercializes medicines to solve therapeutic problems and meaningfully improve people’s lives. We apply innovative drug delivery technology and scientific expertise to redesign important medicines. Our initial focus, supported by our current approved products and late-stage pipeline, is to improve medications and outcomes for patients with central nervous system (CNS) conditions.

Our success is proven

2B+

PharmFilm® doses consumed by patients

200+

Worldwide patents

4

Continents where our products are sold

Aquestive works hand-in-hand with our partners to address their toughest challenges—enhancing existing molecules and providing a development platform for new ones. We have comprehensive capabilities to advance medicines from pipeline to market. Partners can rely on our scientific and regulatory expertise, integrated development capabilities, and world-class clinical and commercial manufacturing operations. More than 2 billion commercial doses have been delivered with our PharmFilm® technology.

News Articles

Aquestive Therapeutics Reports Third Quarter 2019 Financial Results and Raises 2019 Guidance

Increases full year 2019 revenue and earnings guidance Expects to complete its rolling New Drug Application (NDA) submission for Libervant™ (diazepam) Buccal Film around the end of November 2019 Reported successful completion of its Phase 1 dose escalation proof-of-concept study in healthy subjects

 

Aquestive Therapeutics Reaffirms Full Year 2019 Revenue Guidance and Will Announce Third Quarter 2019 Financial Results and Recent Business Highlights on November 6, 2019

WARREN, N.J. , Oct. 15, 2019 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST ), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced, in response to Indivior PLC’s press release issued

 

Aquestive Therapeutics Announces Successful Completion of Phase 1 Trial for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine)

– Represents Significant Proof-of-Concept Milestone for Sublingual Epinephrine Pipeline Product – WARREN, N.J. , Sept. 30, 2019 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST ), a specialty pharmaceutical company focused on developing and commercializing differentiated products to

 

References

1. Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67–76.

2. Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in seizure emergencies: a systematic review. Epilepsy Behav. 2016;63:109–117.

Please complete this form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-561-1900.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

  • To subscribe to receive marketing updates about diazepam buccal film and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

  • To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete this form:

  • To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”